582 related articles for article (PubMed ID: 18061862)
1. Hereditary ovarian cancer--assessing risk and prevention strategies.
Pavelka JC; Li AJ; Karlan BY
Obstet Gynecol Clin North Am; 2007 Dec; 34(4):651-65, vii-viii. PubMed ID: 18061862
[TBL] [Abstract][Full Text] [Related]
2. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
3. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers.
Rebbeck TR
J Clin Oncol; 2000 Nov; 18(21 Suppl):100S-3S. PubMed ID: 11060335
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic oophorectomy in women at increased cancer risk.
Domchek SM; Rebbeck TR
Curr Opin Obstet Gynecol; 2007 Feb; 19(1):27-30. PubMed ID: 17218848
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.
Rebbeck TR; Lynch HT; Neuhausen SL; Narod SA; Van't Veer L; Garber JE; Evans G; Isaacs C; Daly MB; Matloff E; Olopade OI; Weber BL;
N Engl J Med; 2002 May; 346(21):1616-22. PubMed ID: 12023993
[TBL] [Abstract][Full Text] [Related]
6. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
Kauff ND; Satagopan JM; Robson ME; Scheuer L; Hensley M; Hudis CA; Ellis NA; Boyd J; Borgen PI; Barakat RR; Norton L; Castiel M; Nafa K; Offit K
N Engl J Med; 2002 May; 346(21):1609-15. PubMed ID: 12023992
[TBL] [Abstract][Full Text] [Related]
7. Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer.
Kuschel B; Lux MP; Goecke TO; Beckmann MW
Eur J Cancer Prev; 2000 Jun; 9(3):139-50. PubMed ID: 10954253
[TBL] [Abstract][Full Text] [Related]
8. Strategies for ovarian cancer prevention.
Dann RB; Kelley JL; Zorn KK
Obstet Gynecol Clin North Am; 2007 Dec; 34(4):667-86, viii. PubMed ID: 18061863
[TBL] [Abstract][Full Text] [Related]
9. Hereditary ovarian cancer.
Prat J; Ribé A; Gallardo A
Hum Pathol; 2005 Aug; 36(8):861-70. PubMed ID: 16112002
[TBL] [Abstract][Full Text] [Related]
10. Re: "Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations".
Olivier RI; van Beurden M
Gynecol Oncol; 2005 Nov; 99(2):520-1. PubMed ID: 16188301
[No Abstract] [Full Text] [Related]
11. Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome.
Roukos DH; Briasoulis E
Nat Clin Pract Oncol; 2007 Oct; 4(10):578-90. PubMed ID: 17898808
[TBL] [Abstract][Full Text] [Related]
12. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
[TBL] [Abstract][Full Text] [Related]
13. Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions.
Lancaster JM; Powell CB; Kauff ND; Cass I; Chen LM; Lu KH; Mutch DG; Berchuck A; Karlan BY; Herzog TJ;
Gynecol Oncol; 2007 Nov; 107(2):159-62. PubMed ID: 17950381
[TBL] [Abstract][Full Text] [Related]
14. Ovarian cancer associated with inherited mutations in BRCA1 or BRCA2.
Swisher E
Curr Womens Health Rep; 2003 Feb; 3(1):27-32. PubMed ID: 12521547
[TBL] [Abstract][Full Text] [Related]
15. [Recommendations for the management of women with an increased genetic risk of gynaecological cancer].
Verheijen RH; Boonstra H; Menko FH; de Graaff J; Vasen HF; Kenter GG
Ned Tijdschr Geneeskd; 2002 Dec; 146(50):2414-8. PubMed ID: 12518519
[TBL] [Abstract][Full Text] [Related]
16. Predictors of prophylactic bilateral salpingo-oophorectomy compared with gynecologic screening use in BRCA1/2 mutation carriers.
Madalinska JB; van Beurden M; Bleiker EM; Valdimarsdottir HB; Lubsen-Brandsma L; Massuger LF; Mourits MJ; Gaarenstroom KN; van Dorst EB; van der Putten H; Boonstra H; Aaronson NK
J Clin Oncol; 2007 Jan; 25(3):301-7. PubMed ID: 17235045
[TBL] [Abstract][Full Text] [Related]
17. [Hereditary breast cancer: treatment and prevention].
Ejlertsen B; Gerdes AM
Ugeskr Laeger; 2007 Sep; 169(36):2972-5. PubMed ID: 17953871
[TBL] [Abstract][Full Text] [Related]
18. High risk for ovarian cancer in a prospective series is restricted to BRCA1/2 mutation carriers.
Maehle L; Apold J; Paulsen T; Hagen B; Løvslett K; Fiane B; Van Ghelue M; Clark N; Møller P
Clin Cancer Res; 2008 Nov; 14(22):7569-73. PubMed ID: 19010876
[TBL] [Abstract][Full Text] [Related]
19. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.
Rabban JT; Barnes M; Chen LM; Powell CB; Crawford B; Zaloudek CJ
Am J Surg Pathol; 2009 Aug; 33(8):1125-36. PubMed ID: 19440148
[TBL] [Abstract][Full Text] [Related]
20. Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy.
Lamb JD; Garcia RL; Goff BA; Paley PJ; Swisher EM
Am J Obstet Gynecol; 2006 Jun; 194(6):1702-9. PubMed ID: 16731090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]